Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 3,001–3,100 of 15,747
Lin, J., Law, R., Korosec, C. S., Zhou, C. Y., Koh, W. H., Ghaemi, M. S., Samaan, P., Ooi, H. K., Matveev, V., Yue, F., et al. (2022) · Journal of Virology · doi:10.1128/jvi.00509-22 · Cited by 38
“However, some level of protection has been observed in vaccinated individuals prior to serum neutralizing antibody development, indicating that other arms of the immune system likely play a role (8).”
BackgroundmRNA vaccines against respiratory viruses
Whitaker, J. A., Sahly, H. M. E., & Healy, C. M. (2023) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000948 · Cited by 40
“Among adults, BNT162b2 and mRNA-1273 demonstrated 95 and 94% efficacy, respectively, against COVID19 at 2months of follow-up [7,8].”
BackgroundSilvestro, M., Tessitore, A., Orologio, I., Sozio, P., Napolitano, G., Siciliano, M., Tedeschi, G., & Russo, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245914 · Cited by 39
The pathological maelstrom of COVID-19 and cardiovascular disease
Giacca, M., & Shah, A. M. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00029-5 · Cited by 43
Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV-2 Main Protease
Flynn, J. M., Huang, Q. Y. J., Zvornicanin, S. N., Schneider-Nachum, G., Shaqra, A. M., Yılmaz, N. K., Moquin, S. A., Dovala, D., Schiffer, C. A., & Bolon, D. N. A. (2023) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.3c00125 · Cited by 37
Korzun, T., Moses, A. S., Diba, P., Sattler, A. L., Taratula, O. R., Sahay, G., Taratula, O., & Marks, D. L. (2023) · Pharmaceuticals · doi:10.3390/ph16081088 · Cited by 40
Watson, J. A., Kissler, S. M., Day, N., Grad, Y. H., & White, N. J. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00192-22 · Cited by 33
“The risk is strongly age dependent (3) and it is reduced substantially by vaccination (4).”
Analysis of Neurological Adverse Events Reported in VigiBase From COVID-19 Vaccines
Dutta, S., Kaur, R., Charan, J., Bhardwaj, P., Ambwani, S. R., Babu, S., Goyal, J. P., & Haque, M. (2022) · Cureus · doi:10.7759/cureus.21376 · Cited by 36
“This finding was supported by a few previously published clinical studies where a similar type of difference was observed with mRNA-1273, BNT162b2, and AZD1222 vaccines [16,38,42].”
MethodResultZhang, J., Liu, Y., Li, C., Xiao, Q., Zhang, D., Chen, Y., Rosenecker, J., Ding, X., & Guan, S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092182 · Cited by 44
“(3) They may induce a strong immune response when entering humans, causing inflammation and other discomfort, such as local irritation or an allergy [2].”
BackgroundBNT162b2 vaccine uptake and effectiveness in UK healthcare workers – a single centre cohort study
Azamgarhi, T., Hodgkinson, M., Shah, A., Skinner, J. A., Hauptmannova, I., Briggs, T. W. R., & Warren, S. (2021) · Nature Communications · doi:10.1038/s41467-021-23927-x · Cited by 41
Trends in COVID-19 prevalence and mortality: A year in review
James, N., & Menzies, M. (2021) · Physica D Nonlinear Phenomena · doi:10.1016/j.physd.2021.132968 · Cited by 36
Adult-onset Still's disease following mRNA COVID-19 vaccination
Sharabi, A., Shiber, S., & Molad, Y. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108878 · Cited by 35
Barrière, J., Ré, D., Peyrade, F., & Carlès, M. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.06.008 · Cited by 38
Favresse, J., Gillot, C., Bayart, J., David, C., Simon, G., Wauthier, L., Closset, M., Dogné, J., & Douxfils, J. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28164 · Cited by 34
Herzberg, J., Vollmer, T., Fischer, B., Becher, H., Becker, A., Honarpisheh, H., Guraya, S. Y., Strate, T. G., & Knabbe, C. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.11.081 · Cited by 39
“Both vaccines use a two-step approach with a primary and then booster dose after several weeks [4].”
Wang, K., Wong, E. L., Cheung, A. W.-L., Yau, P. S.-Y., Chung, V. C., Wong, C. H.-L., Dong, D., Wong, S. Y. S., & Yeoh, E. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.793533 · Cited by 40
Aseptic meningitis after vaccination of the BNT162b2 mRNA COVID-19 vaccine
Saito, K., Shimizu, T., Suzuki‐Inoue, K., Ishida, T., & Wada, Y. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05543-1 · Cited by 36
Gavriatopoulou, M., Terpos, E., Kastritis, E., Briasoulis, A., Gumeni, S., Ntanasis-Stathopoulos, I., Sklirou, A., Malandrakis, P., Eleutherakis-Papaiakovou, E., Migkou, M., et al. (2021) · Clinical and Experimental Medicine (Testo stampato) · doi:10.1007/s10238-021-00746-4 · Cited by 35
“The BNT162b2 mRNA and the AZD1222 viral vector vaccines against SARS-CoV-2 have shown significant efficacy in healthy adults [7, 8].”
BackgroundNanocarrier vaccine therapeutics for global infectious and chronic diseases
Simnani, F. Z., Singh, D., Patel, P., Choudhury, A., Sinha, A., Nandi, A., Samal, S. K., Verma, S. K., & Panda, P. K. (2023) · Materials Today · doi:10.1016/j.mattod.2023.04.008 · Cited by 42
mRNA delivery via non-viral carriers for biomedical applications
Shuai, Q., Zhu, F., Zhao, M., & Yan, Y. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121020 · Cited by 35
Ahamad, M. M., Aktar, S., Uddin, M. J., Rashed-Al-Mahfuz, M., Azad, A., Uddin, S., Alyami, S. A., Sarker, I. H., Khan, A., Lió, P., et al. (2022) · Healthcare · doi:10.3390/healthcare11010031 · Cited by 50
Self-citationMeng, F., Gao, F., Jia, S., Wú, X., Li, J., Guo, X., Zhang, J., Cui, B., Wu, Z., Wei, M., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00692-3 · Cited by 36
Berry, I., O’Neill, M., Sturrock, S. L., Wright, J. E., Acharya, K. R., Brankston, G., Harish, V., Kornas, K., Maani, N., Naganathan, T., et al. (2021) · Scientific Data · doi:10.1038/s41597-021-00955-2 · Cited by 37
Design, development and clinical translation of CriPec®-based core-crosslinked polymeric micelles
Rijcken, C. J. F., Lorenzi, F. D., Biancacci, I., Hanssen, R., Thewissen, M. M., Hu, Q., Atrafi, F., Liskamp, R. M. J., Mathijssen, R. H. J., Miedema, I. H. C., et al. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114613 · Cited by 39
Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination
Grupel, D., Gazit, S., Schreiber, L., Nadler, V., Wolf, T., Lazar, R., Supino‐Rosin, L., Perez, G., Peretz, A., Ben‐Tov, A., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.025 · Cited by 39
Windsor, I. W., Tong, P., Lavidor, O., Moghaddam, A. S., McKay, L. G. A., Gautam, A. K., Chen, Y., MacDonald, E. A., Yoo, D. K., Griffths, A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo3425 · Cited by 39
Obstetric and Neonatal Outcomes following COVID-19 Vaccination in Pregnancy
Peretz-Machluf, R., Hirsh‐Yechezkel, G., Zaslavsky‐Paltiel, I., Farhi, A., Avisar, N., Lerner‐Geva, L., Meyer, R., Tsur, A., & Yinon, Y. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092540 · Cited by 39
“Since approved by the Food and Drug Administration [5], the mRNA‐based vaccines were found safe and highly effective for preventing symptomatic COVID‐19 disease in the general population aged 16 and older [6,7].”
BackgroundZhu, W. S., Wei, L., Dong, C., Wang, Y., Kim, J. H., Ma, Y., Gonzalez, G. X., & Wang, B. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.10.024 · Cited by 41
Nano-vectors for CRISPR/Cas9-mediated genome editing
Yang, P., Lee, A. Y.-T., Xue, J., Chou, S., Lee, C., Tseng, P., Zhang, T. X., Zhu, Y., Lee, J., Chiou, S., et al. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101482 · Cited by 42
Yamaji, K., Kohsaka, S., Inohara, T., Numasawa, Y., Ando, H., Wada, H., Ishii, H., Amano, T., Miyata, H., & Ikari, Y. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100434 · Cited by 47
Zhang, J. Z., Yeh, H.-W., Walls, A. C., Wicky, B. I. M., Sprouse, K. R., VanBlargan, L. A., Treger, R., Quijano-Rubio, A., Pham, M. N., Kraft, J. C., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01280-8 · Cited by 36
UV222 disinfection of SARS-CoV-2 in solution
Robinson, R., Mahfooz, N., Mejia, O. R., Liu, Y., & Hull, N. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-18385-4 · Cited by 41
Koh, J. S., Hoe, R. H. M., Yong, M. H., Chiew, H. J., Goh, Y., Yong, K. P., Tu, T. M., Chan, D. W. S., Tan, B. Y., Yeo, L. L. L., et al. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120030 · Cited by 40
Travel in the Time of COVID: A Review of International Travel Health in a Global Pandemic
Flaherty, G. T., Hamer, D. H., & Chen, L. H. (2022) · Current Infectious Disease Reports · doi:10.1007/s11908-022-00784-3 · Cited by 43
Lin, W.-Z. S., Bostic, W. K. V., & Malmstadt, N. (2023) · Lab on a Chip · doi:10.1039/d3lc00520h · Cited by 36
Acute myocarditis caused by COVID-19 disease and following COVID-19 vaccination
Kornowski, R., & Witberg, G. (2022) · Open Heart · doi:10.1136/openhrt-2021-001957 · Cited by 37
Nesterenko, P. A., McLaughlin, J., Tsai, B. L., Sojo, G. B., Cheng, D., Zhao, D. Y., Mao, Z., Bangayan, N. J., Obusan, M. B., Su, Y., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110167 · Cited by 36
Tartof, S. Y., Slezak, J. M., Puzniak, L., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3989856 · Cited by 35
Immunogenicity of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines
Naranbhai, V., Garcia-Beltran, W., Mairena, C. B., Thierauf, J., Chang, C. C., Kirkpatrick, G., Onozato, M., Cheng, J., Denis, K. J. S., Lam, E., et al. (2021) · medRxiv · doi:10.1101/2021.07.18.21260732 · Cited by 8
“Vaccination with mRNA-1273[1] (100ug, Moderna), BNT162b2[2] (30ug, Pfizer) and Ad26.”
Influenza Viruses: Innate Immunity and mRNA Vaccines
Lee, S., & Ryu, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.710647 · Cited by 39
“However, all of the above-mentioned excipients were not included in the Pfizer-BioNTech COVID-19 mRNA vaccine and no cases of anaphylaxis were observed in large-scale phase 2/3 clinical trials; thus, these events are unexpected (111, 112).”
BackgroundKamanzi, A., Zhang, Y., Gu, Y., Liu, F., Berti, R., Wang, B. L., Saadati, F., Ciufolini, M. A., Kulkarni, J. A., Cullis, P. R., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c12981 · Cited by 37
An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer
Suryadevara, N., Shiakolas, A. R., VanBlargan, L. A., Binshtein, E., Chen, R. E., Case, J. B., Kramer, K. J., Armstrong, E., Myers, L., Trivette, A., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159062 · Cited by 32
Vaccines and variants: Modelling insights into emerging issues in COVID-19 epidemiology
Caldwell, J. M., Le, X., McIntosh, L., Meehan, M. T., Ogunlade, S. T., Ragonnet, R. R., O’Neill, G. K., Trauer, J. M., & McBryde, E. S. (2021) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2021.07.002 · Cited by 40
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
(2022) · doi:10.1101/2022.03.13.22272308 · Cited by 228
Eslami, M., Dowlat, B. F., Yaghmayee, S., Habibian, A., Keshavarzi, S., Oksenych, V., & Naderian, R. (2025) · Vaccines · doi:10.3390/vaccines13060588 · Cited by 54
Malavazos, A. E., Basilico, S., Iacobellis, G., Milani, V., Cardani, R., Boniardi, F., Dubini, C., Prandoni, I., Capitanio, G., Renna, L. V., et al. (2021) · Obesity · doi:10.1002/oby.23353 · Cited by 39
“the causative agent of COVID-19, hold great promise for curbing the spread of infection and accelerating the timeline towards a possible level of herd immunity [4].”
BackgroundA case of Guillain–Barre syndrome following Pfizer COVID-19 vaccine
Rao, S. J., Khurana, S., Murthy, G., Dawson, E. T., Jazebi, N., & Haas, C. J. (2021) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2021.1954284 · Cited by 36
“fever with more people noticing symptoms after the second dose [6,7].”
BackgroundSimulation-driven design of stabilized SARS-CoV-2 spike S2 immunogens
Nuqui, X., Casalino, L., Zhou, L., Shehata, M., Wang, A., Tse, A. L., Ojha, A. A., Kearns, F. L., Rosenfeld, M. A., Miller, E. H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50976-9 · Cited by 35
“4 Vaccines have provided protection against severe COVID-19 disease, hospitalization, and mortality, 5,6 but their efficacy has been challenged by the continual emergence of several SARS-CoV-2 variants of concern (VOCs), including Alpha, Beta, Delta, Gamma, multiple Omicron sublineages BA.1, BA.2,…”
BackgroundJanus kinase signaling as risk factor and therapeutic target for severe SARS‐CoV‐2 infection
Solimani, F., Meier, K., & Ghoreschi, K. (2021) · European Journal of Immunology · doi:10.1002/eji.202149173 · Cited by 38
Mohammadi, Y., Nezafat, N., Negahdaripour, M., Eskandari, S., & Zamani, M. (2022) · Immunologic Research · doi:10.1007/s12026-022-09351-3 · Cited by 44
Carnitine palmitoyltransferase II deficiency and post-COVID vaccination rhabdomyolysis
Tan, A., Stępień, K. M., & Narayana, S. T. K. (2021) · QJM · doi:10.1093/qjmed/hcab077 · Cited by 35
Katz, J. D., Bouley, A. J., Jungquist, R. M., Douglas, E. A., O'Shea, I. L., & Lathi, E. S. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103382 · Cited by 38
Ioannou, G. N., Green, P. K., Fan, V. S., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.4347 · Cited by 35
Chen, Z., Kelly, K., Cheng, H., Dong, X., Hedger, A. K., Li, L., Sontheimer, E. J., & Watts, J. K. (2023) · GEN Biotechnology · doi:10.1089/genbio.2023.0045 · Cited by 41
Barman, T. K., Singh, A. K., Bonin, J. L., Nafiz, T. N., Salmon, S. L., & Metzger, D. W. (2022) · JCI Insight · doi:10.1172/jci.insight.159422 · Cited by 37
Systematic modulation of the lipid composition enables the tuning of liposome cellular uptake
Mateos‐Maroto, A., Gai, M., Brückner, M., Marques, R. D. C., Harley, I., Simon, J., Mailänder, V., Morsbach, S., & Landfester, K. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.12.058 · Cited by 38
Barateau, V., Peyrot, L., Saade, C., Pozzetto, B., Brengel‐Pesce, K., Elsensohn, M., Allatif, O., Guibert, N., Compagnon, C., Mariano, N., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.ade0550 · Cited by 35
Galati, D., Zanotta, S., Capitelli, L., & Bocchino, M. (2021) · Allergy · doi:10.1111/all.15004 · Cited by 33
Chiarucci, M., Paolasini, S., Isidori, A., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.737300 · Cited by 35
“OnMarch 2021, as suggested by GITMO and SIE indications (5), 50 HSCT recipients (38 autologous HSCT and 12 allogeneic HSCT, all transplanted in our Unit) (Table 1) were vaccinated with the mRNA-based SARS-CoV-2 vaccine BNT162b2 (PfizerBioNTech), according to the standard protocol (two doses of 30 μg administered three…”
MethodYang, Y., Shi, W., Abiona, O. M., Nazzari, A. F., Olia, A. S., Ou, L., Phung, E., Stephens, T., Tsybovsky, Y., Verardi, R., et al. (2021) · Vaccines · doi:10.3390/vaccines9020073 · Cited by 38
Effect of vaccination to control COVID-19 with fractal fractional operator
Amin, M., Farman, M. T., Akgül, A., & Alqahtani, R. T. (2021) · Alexandria Engineering Journal · doi:10.1016/j.aej.2021.09.006 · Cited by 37
Savva, D., Battineni, G., Amenta, F., & Nittari, G. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.066 · Cited by 41
Recommendations from the ICM-VTE: General
Delegates, T. I.-V. G. (2022) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.21.01531 · Cited by 38
Adenovirus vector and mRNA vaccines: Mechanisms regulating their immunogenicity
Provine, N. M., & Klenerman, P. (2022) · European Journal of Immunology · doi:10.1002/eji.202250022 · Cited by 40
Mair, M. J., Berger, J. M., Mitterer, M., Gansterer, M., Bathke, A. C., Trutschnig, W., Berghoff, A. S., Perkmann, T., Haslacher, H., Lamm, W. W., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.01.019 · Cited by 37
“To add further, AE rates after vaccine administration in our cohort were comparable to those observed in the general population [7].”
Microneedle systems for delivering nucleic acid drugs
Noh, I., Lee, K., & Rhee, Y.-S. (2022) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-021-00558-4 · Cited by 44
A Meta-Analysis on the Safety and Immunogenicity of Covid-19 Vaccines
Ashmawy, R., Hamdy, N. A., Elhadi, Y. A. M., Alqutub, S. T., Esmail, O. F., Abdou, M. S. M., Reyad, O. A., El-Ganainy, S. O., Gad, B. K., El-Deen, A. E.-S. N., et al. (2022) · Journal of Primary Care & Community Health · doi:10.1177/21501319221089255 · Cited by 38
Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics
Yang, W., Cao, J., Cheng, H., Chen, L., Yu, M., Chen, Y., & Cui, X. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.11.014 · Cited by 48
“The authorized use and increasing global vaccination rate of two effective and safe mRNA-based vaccines (BNT162b2 [1] and mRNA-1273 [2]) against COVID-19 have successfully reduced the transmission of coronaviruses and deadly illness, making extraordinary contributions to helping people get through the difficult pandem…”
The herd-immunity threshold must be updated for multi-vaccine strategies and multiple variants
Yadegari, I., Omidi, M., & Smith, S. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-00083-2 · Cited by 38
Effectiveness of the 2023–2024 Formulation of the COVID-19 Messenger RNA Vaccine
Shrestha, N. K. M., Burke, P. C., Nowacki, A. S., & Gordon, S. M. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae132 · Cited by 33
The risk of miscarriage following COVID-19 vaccination: a systematic review and meta-analysis
Rimmer, M. P., Teh, J. J., Mackenzie, S. C., & Wattar, B. H. A. (2023) · Human Reproduction · doi:10.1093/humrep/dead036 · Cited by 38
Awasthi, S., Knox, J. J., Desmond, A., Alameh, M.-G., Gaudette, B. T., Lubinski, J. M., Naughton, A., Hook, L. M., Egan, K. P., Tam, Y. K., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152310 · Cited by 34
Effectiveness estimates of three COVID-19 vaccines based on observational data from Puerto Rico
Robles-Fontán, M. M., Nieves, E. G., Cardona-Gerena, I., & Irizarry, R. A. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100212 · Cited by 35
Seasonal quadrivalent mRNA vaccine prevents and mitigates influenza infection
Kackos, C. M., DeBeauchamp, J., Davitt, C. J. H., Lonzarić, J., Sealy, R. E., Hurwitz, J. L., Samsa, M. M., & Webby, R. J. (2023) · npj Vaccines · doi:10.1038/s41541-023-00752-5 · Cited by 40
Balcells, M. E., Corre, N. L., Durán, J., Ceballos, M. E., Vizcaya, C., Mondaca, S., Dib, M., Ricardo Rabagliati, B., Mauricio Sarmiento, M., Burgos, P. I., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac167 · Cited by 46
Li, H., Guo, L., Zheng, H., Li, J., Zhao, X., Li, J., Liang, Y., Yang, F., Zhao, Y., Yang, J., et al. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00208 · Cited by 33
Prediction and Evolution of the Molecular Fitness of SARS-CoV-2 Variants: Introducing SpikePro
Pucci, F., & Rooman, M. J. (2021) · Viruses · doi:10.3390/v13050935 · Cited by 35
“10 May20 Oct20 Mar21 [0,1] [1,5] [5,10] >10 0.”
BackgroundHielscher, F., Schmidt, T., Klemis, V., Wilhelm, A., Marx, S., Abu‐Omar, A., Ziegler, L., Guckelmus, C., Urschel, R., Sester, U., et al. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105321 · Cited by 36
“1% efficacious, respectively, at preventing severe COVID-19 illness from the parental viral strains [6,7].”
BackgroundBarbeau, D. J., Martin, J. M., Carney, E., Dougherty, E., Doyle, J., Dermody, T. S., Hoberman, A., Williams, J. V., Michaels, M. G., Alcorn, J. F., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00504-x · Cited by 45
“Black, non-Hispanic 1 (4) 0 (0) 1 (4) 155,798 (12.”
InfluentialHuang, X., Chuang, L. I. U., Sharma, S. N., You, X., Chen, S., Li, Y., Liu, H.-J., Liu, B., Saiding, Q., Chen, W., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adu1493 · Cited by 43
Mahmud, M. S., Kamrujjaman, M., Adan, M. M. I. Y., Hossain, M. A., Rahman, M. M., Islam, M. S., Mohebujjaman, M., & Molla, M. M. (2021) · Infectious Disease Modelling · doi:10.1016/j.idm.2021.11.002 · Cited by 45
“Notably, most volunteers had these side effects after completing the final dose (Polack et al., 2020).”
BackgroundDesai, A. P., Desai, A. P., & Loomis, G. J. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.06.058 · Cited by 34
“During the clinical trial for the Pfizer-BioNTech COVID19 mRNA vaccine, the majority of the adverse effects were shortterm, mild-to-moderate pain at the injection site, fatigue, and headache [2].”
BackgroundPugh, J., Savulescu, J., Brown, R. C. H., & Wilkinson, D. J. C. (2022) · Journal of Medical Ethics · doi:10.1136/medethics-2021-107956 · Cited by 38
“21 22 As time passes, we will continue to learn more about the duration of vaccine-induced immunity, but data suggest that vaccine efficacy declines over time.”
BackgroundNeurologic Manifestations and Complications of COVID-19
Hensley, M. K., Markantone, D. M., & Prescott, H. C. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042320-010427 · Cited by 37
The Repurposed Drugs Suramin and Quinacrine Cooperatively Inhibit SARS-CoV-2 3CLpro In Vitro
Eberle, R. J., Olivier, D. S., do Amaral, M. S., Gering, I., Willbold, D., Arni, R. K., & Coronado, M. A. (2021) · Viruses · doi:10.3390/v13050873 · Cited by 38
Sezgin, D., Dost, A., & Esin, M. (2021) · International Nursing Review · doi:10.1111/inr.12740 · Cited by 54
Ci, L., Hard, M., Zhang, H., Gandham, S. K., Hua, S. S., Wickwire, J., Wehrman, T., Slauter, R., Auerbach, A. D., Kenney, M., et al. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.122.000980 · Cited by 41
VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants
Prates-Syed, W. A., Chaves, L. C. S., Crema, K. P., Vuitika, L., Lira, A. A. D. L., Côrtes, N., Kersten, V., Guimarães, F. E. G., Sadraeian, M., da Silva, F. L. B., et al. (2021) · Vaccines · doi:10.3390/vaccines9121409 · Cited by 39
“[26] against symptomatic cases and a substantial reduction of hospitalizations and deaths in the United Kingdom, Israel, and other countries [143–145].”
BackgroundPulmonary delivery of mucosal nanovaccines
Tang, W., Zhang, Y., & Zhu, G. (2022) · Nanoscale · doi:10.1039/d1nr06512b · Cited by 42
Durable lymph-node expansion is associated with the efficacy of therapeutic vaccination
Najibi, A. J., Lane, R. S., Sobral, M. C., Bovone, G., Kang, S. J., Freedman, B. R., Estupinan, J. G., Elósegui-Artola, A., Tringides, C. M., Dellacherie, M. O., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01209-3 · Cited by 41
Viana, J. F., Bergman, M., Gonçalves, L. A., Duarte, N., Coutinho, T. P., Borges, P., Diwo, C., Castro, R., Matoso, P., Malheiro, V., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27761-z · Cited by 39
Bilateral EK Rejection After COVID-19 Vaccine
Abousy, M., Bohm, K. J., Prescott, C. R., et al. (2021) · Eye & Contact Lens Science & Clinical Practice · doi:10.1097/icl.0000000000000840 · Cited by 35
Synthetic circRNA therapeutics: innovations, strategies, and future horizons
Cai, J., Qiu, Z., Cho, W. C. S., Liu, Z., Chen, S., Li, H., Chen, K., Li, Y., Zuo, C., & Qiu, M. (2024) · MedComm · doi:10.1002/mco2.720 · Cited by 45
Salmanton‐García, J., Marchesi, F., Farina, F., Weinbergerová, B., Itri, F., Dávila, J., Martín‐Pérez, S., Glenthøj, A. B., Hersby, D. S., da Silva, M. G., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102553 · Cited by 42
Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine
Fitzpatrick, D., McVinnie, D. S., Jackson, L. A., Crowther, G., Geevarughese, A., Cannon, K. D., Garcia, L. M., Puebla, Y. P., Yi, Z., Cunliffe, L., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2416779 · Cited by 54
Self-citationOptimization of ionizable lipids for aerosolizable mRNA lipid nanoparticles
Lewis, M. M., Soto, M. R., Maier, E. Y., Wulfe, S., Bakheet, S., Obregon, H., & Ghosh, D. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10580 · Cited by 43
“17,18 This carrier can be widely used for many indications and more specifically From our findings, we would like to highlight possible routes of exploration for future work.”
BackgroundCaldwell, J. M., de Lara-Tuprio, E. P., Teng, T. R. Y., Estuar, M. R. J. E., Sarmiento, R. F., Abayawardana, M., Leong, R. N. F., Gray, R. T., Wood, J., Le, L., et al. (2021) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2021.100211 · Cited by 48
Santovito, L. S., & Pinna, G. (2021) · Inflammation Research · doi:10.1007/s00011-021-01476-9 · Cited by 35
Abukhalil, A. D., Shatat, S. S., Abushehadeh, R. R., Al-Shami, N. A., Naseef, H., & Rabba, A. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-022-07974-3 · Cited by 43
“Enlarged axillary nodes are a normal response caused by a robust vaccine-elicited immune response due to the proliferation of rapidly activated immune cells (residual effector cells) from previous doses [30, 31].”
Background
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.